8-K
KalVista Pharmaceuticals, Inc. (KALV)
UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
| Date of Report (Date of earliest event reported): March 11, 2024 |
|---|
KALVISTA PHARMACEUTICALS, INC.
(Exact name of Registrant as Specified in Its Charter)
| Delaware | 001-36830 | 20-0915291 |
|---|---|---|
| (State or Other Jurisdiction<br>of Incorporation) | (Commission File Number) | (IRS Employer<br>Identification No.) |
| 55 Cambridge Parkway<br><br>Suite 901E | ||
| Cambridge, Massachusetts | 02142 | |
| (Address of Principal Executive Offices) | (Zip Code) | |
| Registrant’s Telephone Number, Including Area Code: 857 999-0075 | ||
| --- |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading<br>Symbol(s) | Name of each exchange on which registered |
|---|---|---|
| Common Stock, $0.001 par value per share | KALV | The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On March 11, 2024, KalVista Pharmaceuticals, Inc. (the “Company”) reported its financial results for the fiscal quarter ended January 31, 2024. A copy of the press release issued by the Company is furnished as Exhibit 99.1 to this report.
The information furnished with Item 2.02 of this report, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Exchange Act or under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit<br><br>Number | Description |
|---|---|
| 99.1 | Press release dated March 11, 2024 |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| KALVISTA PHARMACEUTICALS, INC. | |||
|---|---|---|---|
| Date: | March 11, 2024 | By: | /s/ Benjamin L. Palleiko |
| Benjamin L. Palleiko<br>Chief Executive Officer<br>(Principal Executive, Financial and Accounting Officer) |
EX-99.1
Exhibit 99.1
KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update
Sebetralstat Phase 3 KONFIDENT clinical trial met all endpoints and demonstrated a favorable safety profile as first oral on-demand therapy for hereditary angioedema -
CEO transition supports ongoing evolution into commercial company -
Cambridge, MA and Salisbury, England, March 11, 2024 –KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today provided an operational update and released financial results for the third fiscal quarter ended January 31, 2024.
“This has been an exciting and busy period for KalVista, as we achieved key milestones with the release of our phase 3 KONFIDENT data and the completion of a substantial financing,” said Ben Palleiko, Chief Executive Officer of KalVista. “We remain on track to file the NDA with the U.S. Food and Drug Administration in the first half of this year, and we look forward to presenting further phase 3 data for sebetralstat at upcoming patient and medical meetings. We also continue to grow the commercial organization to enable us to deliver on the promise of providing the first oral, on-demand treatment option to the HAE community.”
Third Fiscal Quarter and Recent Business Highlights:
• In February, the Company announced positive topline data from the Phase 3 KONFIDENT clinical trial evaluating the safety and efficacy of sebetralstat as the potential first oral, on-demand therapy for hereditary angioedema (HAE). KONFIDENT was the largest and most representative trial ever conducted in HAE, enrolling a total of 136 patients from 66 clinical sites across 20 countries. Eligible participants included adolescents, patients using long-term prophylaxis, and the trial evaluated all attack severities and locations. The clinical trial met all primary and key secondary endpoints across both the 300 and 600 mg doses and demonstrated a safety profile similar to placebo.
• Also in February, KalVista closed an underwritten offering to sell an aggregate of 7,016,312 shares of common stock at price of $15.25 per share and pre-funded warrants to purchase up to 3,483,688 shares of common stock at a price of $15.249 per pre-funded warrant. The net proceeds from the offering were approximately $150.1 million and are expected to provide funding into 2026.
• The Company announced that Benjamin L. Palleiko, the Company’s prior President, CBO and CFO, was appointed as Chief Executive Officer and a director of the Company. This appointment is the result of a planned transition as KalVista prepares to become a commercial entity following the success of the KONFIDENT Phase 3 trial for its program sebetralstat.
• The UK Medicines and Healthcare products Regulatory Agency (MHRA) awarded the Innovation Passport for sebetralstat, providing entry to the UK Innovative Licensing and
Exhibit 99.1
Access Pathway (ILAP), which aims to accelerate time to market and facilitate patient access to innovative medicines.
• Presented additional Phase 3 KONFIDENT data as well as data on unmet need in HAE from a patient perspective at the 2024 American Academy of Allergy Asthma & Immunology Annual Meeting (AAAAI) in Washington, D.C.
• Announced publication of the first report of a potent and specific Factor XIIa inhibitor with high oral availability in a peer-reviewed journal. The Frontiers in Pharmacology article describes the pharmacology of a representative compound from KalVista’s portfolio of structurally diverse, oral Factor XII inhibitors.
Third Fiscal Quarter Financial Results:
Revenue: No revenue was recognized for the three months ended January 31, 2024, or January 31, 2023.
R&D Expenses: Research and development expenses were $22.5 million for the three months ended January 31, 2024, compared to $20.1 million for the same period in the prior fiscal year. The increase in R&D expenses during the quarter primarily reflects the ongoing Phase 3 KONFIDENT and KONFIDENT-S trials.
G&A Expenses: General and administrative expenses were $10.6 million for the three months ended January 31, 2024, compared to $6.9 million for the same period in the prior fiscal year. The increase in G&A expenses was primarily due to increases in employee-related expenses and commercial planning expenses.
Net Loss: Net loss was $29.0 million, or $(0.84) per weighted average basic and diluted share, for the three months ended January 31, 2024, compared to net loss of $21.3 million, or $(0.75) per weighted average basic and diluted share for the same period in the prior fiscal year. The increase in net loss primarily resulted from the increase in operating expenses, primarily research and development.
Cash Position: Cash, cash equivalents and marketable securities were $75.6 million as of January 31, 2024, compared to $149.4 million as of April 30, 2023. The decrease in the net cash and marketable securities position was due to cash consumption from operating expenses.
About KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors for diseases with significant unmet need. KalVista disclosed positive phase 3 data for the KONFIDENT trial for its oral, on-demand therapy sebetralstat in February 2024. The Company anticipates submitting a new drug application to the U.S. Food and Drug Administration (FDA) for sebetralstat in the first half of 2024 and expects to file for approval in Europe and Japan later in 2024. In addition, KalVista’s oral Factor XIIa inhibitor program represents a new generation of therapies that may further improve the treatment for people living with HAE and other diseases.
For more information about KalVista, please visit www.kalvista.com.
Exhibit 99.1
Forward-Looking Statements
This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, timing or outcomes of communications with the FDA, our expectations about safety and efficacy of our product candidates, our ability to obtain regulatory approvals for sebetralstat and other candidates in development, the success of any efforts to commercialize sebetralstat, the ability of sebetralstat and other candidates in development to treat HAE or other diseases, and the future progress and potential success of our oral Factor XIIa program. Further information on potential risk factors that could affect our business and financial results are detailed in our filings with the Securities and Exchange Commission, including in our annual report on Form 10-K for the year ended April 30, 2023, our quarterly reports on Form 10-Q, and our other reports that we may make from time to time with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Contact:
KalVista Pharmaceuticals, Inc.
Jarrod Aldom
Vice President, Corporate Communications
(201) 705-0254
jarrod.aldom@kalvista.com
Ryan Baker
Head, Investor Relations
(617) 771-5001
ryan.baker@kalvista.com
Exhibit 99.1
| KalVista Pharmaceuticals Inc. | |||||
|---|---|---|---|---|---|
| Condensed Consolidated Balance Sheets | |||||
| (in thousands, except share and per share amounts) | |||||
| (Unaudited) | |||||
| April 30, | |||||
| 2023 | |||||
| Assets | |||||
| Current assets: | |||||
| Cash and cash equivalents | 23,056 | $ | 56,238 | ||
| Marketable securities | 52,530 | 93,137 | |||
| Research and development tax credit receivable | 23,011 | 16,568 | |||
| Prepaid expenses and other current assets | 5,506 | 6,383 | |||
| Total current assets | 104,103 | 172,326 | |||
| Property and equipment, net | 2,423 | 2,948 | |||
| Right of use assets | 7,045 | 7,822 | |||
| Other assets | 397 | 106 | |||
| Total assets | 113,968 | $ | 183,202 | ||
| Liabilities and stockholders' equity | |||||
| Current liabilities: | |||||
| Accounts payable | 3,101 | $ | 4,817 | ||
| Accrued expenses | 14,840 | 9,128 | |||
| Lease liability - current portion | 1,187 | 1,087 | |||
| Total current liabilities | 19,128 | 15,032 | |||
| Long-term liabilities: | |||||
| Lease liability - net of current portion | 6,257 | 7,145 | |||
| Total long-term liabilities | 6,257 | 7,145 | |||
| Stockholders’ equity: | |||||
| Common stock, 0.001 par value | 34 | 34 | |||
| Additional paid-in capital | 516,920 | 507,133 | |||
| Accumulated deficit | (425,077 | ) | (343,082 | ) | |
| Accumulated other comprehensive loss | (3,294 | ) | (3,060 | ) | |
| Total stockholders’ equity | 88,583 | 161,025 | |||
| Total liabilities and stockholders' equity | 113,968 | $ | 183,202 |
All values are in US Dollars.
Exhibit 99.1
| KalVista Pharmaceuticals Inc. | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Condensed Consolidated Statement of Operations | ||||||||||||
| (in thousands, except share and per share amounts) | ||||||||||||
| (Unaudited) | ||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||
| January 31, | January 31, | |||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||
| Revenue | $ | — | $ | — | $ | — | $ | — | ||||
| Operating expenses: | ||||||||||||
| Research and development | 22,523 | 20,063 | 60,919 | 56,325 | ||||||||
| General and administrative | 10,628 | 6,882 | 31,071 | 22,818 | ||||||||
| Total operating expenses | 33,151 | 26,945 | 91,990 | 79,143 | ||||||||
| Operating loss | (33,151 | ) | (26,945 | ) | (91,990 | ) | (79,143 | ) | ||||
| Other income: | ||||||||||||
| Interest income | 684 | 732 | 2,383 | 1,424 | ||||||||
| Foreign currency exchange rate gain (loss) | 1,120 | 597 | 277 | (237 | ) | |||||||
| Other income | 2,319 | 4,313 | 7,335 | 11,354 | ||||||||
| Total other income | 4,123 | 5,642 | 9,995 | 12,541 | ||||||||
| Net loss | $ | (29,028 | ) | $ | (21,303 | ) | $ | (81,995 | ) | $ | (66,602 | ) |
| Net loss per share, basic and diluted | $ | (0.84 | ) | $ | (0.75 | ) | $ | (2.37 | ) | $ | (2.58 | ) |
| Weighted average common shares outstanding, basic and diluted | 34,723,379 | 28,278,453 | 34,567,853 | 25,810,369 |
Exhibit 99.1
| KalVista Pharmaceuticals Inc. | |||||
|---|---|---|---|---|---|
| Condensed Consolidated Statements of Cash Flows | |||||
| (in thousands, unaudited) | |||||
| 2023 | |||||
| Cash flows from operating activities | |||||
| Net loss | (81,995 | ) | $ | (66,602 | ) |
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||
| Depreciation and amortization | 597 | 530 | |||
| Stock-based compensation expense | 9,172 | 7,481 | |||
| Realized (gain) loss from sale of marketable securities | (1,130 | ) | 84 | ||
| Non-cash operating lease expense | (11 | ) | 52 | ||
| Amortization of premium on marketable securities | 88 | 890 | |||
| Foreign currency exchange loss (gain) | 596 | (1,339 | ) | ||
| Changes in operating assets and liabilities: | |||||
| Research and development tax credit receivable | (6,215 | ) | 2,049 | ||
| Prepaid expenses and other current assets | 906 | 4,440 | |||
| Accounts payable | (1,778 | ) | (1,911 | ) | |
| Accrued expenses | 5,644 | 1,701 | |||
| Net cash used in operating activities | (74,126 | ) | (52,625 | ) | |
| Cash flows from investing activities | |||||
| Purchases of marketable securities | (47,687 | ) | (63,757 | ) | |
| Sales and maturities of marketable securities | 89,475 | 112,509 | |||
| Acquisition of property and equipment | (27 | ) | (1,127 | ) | |
| Website development costs | (294 | ) | — | ||
| Net cash provided by investing activities | 41,467 | 47,625 | |||
| Cash flows from financing activities | |||||
| Issuance of common stock from equity incentive plans | 616 | 482 | |||
| Issuance of common stock, net of offering expenses of 0.3 million | — | 56,582 | |||
| Issuance of pre-funded warrants, net of offering expenses | — | 1,085 | |||
| Net cash provided by financing activities | 616 | 58,149 | |||
| Effect of exchange rate changes on cash and cash equivalents | (1,139 | ) | 1,168 | ||
| Net (decrease) increase in cash and cash equivalents | (33,182 | ) | 54,317 | ||
| Cash and cash equivalents at beginning of period | 56,238 | 30,732 | |||
| Cash and cash equivalents at end of period | 23,056 | $ | 85,049 |
All values are in US Dollars.